articleJournal of the American Chemical SocietyDec 1, 2014Closed access

Multivalent N -Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing

Alnylam Pharmaceuticals (United States) · Centre for Human Drug Research · +1 more institution

PubMed
Indexed incrossrefpubmed

Abstract

Conjugation of small interfering RNA (siRNA) to an asialoglycoprotein receptor ligand derived from N-acetylgalactosamine (GalNAc) facilitates targeted delivery of the siRNA to hepatocytes in vitro and in vivo. The ligands derived from GalNAc are compatible with solid-phase oligonucleotide synthesis and deprotection conditions, with synthesis yields comparable to those of standard oligonucleotides. Subcutaneous (SC) administration of siRNA-GalNAc conjugates resulted in robust RNAi-mediated gene silencing in liver. Refinement of the siRNA chemistry achieved a 5-fold improvement in efficacy over the parent design in vivo with a median effective dose (ED50) of 1 mg/kg following a single dose. This enabled the SC…

Citation impact

1,067
total citations
FWCI
27.31
Percentile
100%
References
38
Citations per year

Authors

25

Topics & keywords

Keywords
  • Gene silencing
  • RNA interference
  • Small interfering RNA
  • Chemistry
  • Asialoglycoprotein receptor
  • In vivo
  • Oligonucleotide
  • In vitro
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.